BioXcel Therapeutics logged a 2.0% change during today's evening session, and is now trading at a price of $4.03 per share. On average, analysts give it a target price of $19.5.
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The small-cap company is based in the United States.
Make Sure to Consider the Following Before Buying BioXcel Therapeutics:
-
BioXcel Therapeutics has moved -72.0% over the last year.
-
BTAI has a forward P/E ratio of -1.7 based on its EPS guidance of -2.34.
-
Over the last 5 years, earnings per share (EPS) have been growing at a compounded average rate of -41.2%.
-
The company has a price to earnings growth (PEG) ratio of 0.0.
-
Its Price to Book (P/B) ratio is 20.15
BioXcel Therapeutics Has None
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-03-16 | -135,341 | -139 | -135,202 | -65.47 |
| 2022-03-11 | -82,153 | -445 | -81,708 | -23.74 |
| 2021-03-12 | -66,350 | -316 | -66,034 | -151.74 |
| 2020-03-09 | -27,101 | -870 | -26,231 | -99.19 |
| 2019-03-12 | -13,509 | -340 | -13,169 |
None
